A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir
and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in
treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.